Boston Scientific nabs French coverage
This article was originally published in The Gray Sheet
Executive Summary
The French government will pay for Taxus Liberté after the drug-eluting stent received reimbursement approval on Feb. 15. The firm notes that the paclitaxel-eluting stent will now be available to patients at both private and public hospitals in France. The device was CE marked in September 2005. According to the firm, France was slow to adopt and reimburse the original Taxus stent (1"The Gray Sheet" Feb. 9, 2004, p. 20)...
You may also be interested in...
Boston Scientific Taxus Inventory Of 150,000 Planned For U.S. Launch
Boston Scientific projects a 60% U.S. drug-eluting stent market penetration "right out of the gate" for its soon-to-be-launched Taxus, according to Senior VP and Cardiovascular Group President Paul LaViolette
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.